Department of Urology, University of California, San Francisco, CA, USA.
BJU Int. 2012 May;109(10):1520-4. doi: 10.1111/j.1464-410X.2011.10605.x. Epub 2011 Oct 14.
Study Type - Therapy (case series) Level of Evidence 4. What's known on the subject? and What does the study add? Although phosphodiesterase inhibitor use post radical prostatectomy improves potency, little is known about its affects on sexual bother. We found no difference in sexual bother scores between patients who use and do not use phosphodiesterase inhibitors. This suggests that the current definition of potency, inclusive of medication use, is valid with respect to sexual bother.
To determine whether the current definition of potency, inclusive of phosphodiesterase inhibitor (PDEi) use, is valid with respect to sexual bother (SB). This will be assessed by characterizing the effect of PDEi use on SB scores in men who are potent post radical prostatectomy.
The study population consisted of patients who were potent both before and after radical prostatectomy, with at least 2 years of follow-up. Disease-specific quality of life data were evaluated by the University of California, Los Angeles, Prostate Cancer Index (PCI) survey. The relationships between changes in sexual function (SF) and SB and use of PDEi over time were evaluated by mixed model analysis controlling for age, clinical risk group, marital status, and time of PCI assessment.
Of the 246 patients who met the study criteria, 39% reported PDEi use at some point after treatment. PDEi use was not associated with improved SF (P= 0.81). Furthermore, PDEi use was not associated with a change in SB (P= 0.36). Both SF and SB were significantly associated with time of assessment and age, and SF and SB each improved over time. In addition, SB was significantly associated with marital status.
In this analysis, there was no difference in SF scores between men who were potent with or without the use of PDEi. Furthermore, there was no difference in SB scores between men who were potent with or without the use of PDEi. This suggests that the current, inclusive, definition of potency is valid with respect to SB.
确定当前的勃起功能定义(包括磷酸二酯酶抑制剂(PDEi)的使用)在与性困扰(SB)相关方面是否有效。本研究将通过评估 PDEi 使用对根治性前列腺切除术后勃起功能仍然保留的男性 SB 评分的影响来实现这一目标。
研究人群包括根治性前列腺切除术前和术后勃起功能均正常且随访时间至少 2 年的患者。通过加利福尼亚大学洛杉矶分校前列腺癌指数(UCLA-PCI)调查评估疾病特异性生活质量数据。通过混合模型分析,控制年龄、临床风险组、婚姻状况和 PCI 评估时间,评估性功能(SF)和 SB 变化以及随时间使用 PDEi 的关系。
在符合研究标准的 246 名患者中,39%的患者在治疗后某个时间点报告使用 PDEi。PDEi 的使用与 SF 改善无关(P=0.81)。此外,PDEi 的使用与 SB 变化无关(P=0.36)。SF 和 SB 均与评估时间和年龄显著相关,SF 和 SB 均随时间改善。此外,SB 与婚姻状况显著相关。
在本分析中,有或没有 PDEi 使用的勃起功能正常的男性之间 SF 评分无差异。此外,有或没有 PDEi 使用的勃起功能正常的男性之间 SB 评分无差异。这表明当前包括 PDEi 使用的勃起功能定义在与 SB 相关方面是有效的。